Drugssquare, one of the world's leading generic and specialty online pharmaceutical companies, announced the addition of [b]Hertraz 440 mg Injection[/b], in their wide-ranging spread of product list.

The product, which is manufactured by Mylan under the brand name Hertraz, is a biosimilar to Roche's Herceptin. It is indicated for the treatment of HER2-positive [b]metastatic breast cancer[/b] and is available in strength of 440 mg. Hertraz contains Trastuzumab that sticks to the HER2 protein (a type of HER that can play a role in the development of breast cancer), and it prevents the epidermal growth factor from getting into the cancer cells. In this way, Trastuzumab stops the breast cancer cells from reproducing uncontrollably.

Drugssquare is delighted to offer Hertraz (Trastuzumab) to the thousands of patients suffering from metastatic breast cancer who are in need of a high quality, more affordable treatment option. They look forward to expanding their portfolio of high quality and affordable biosimilar offerings, particularly in the oncology care segment, in USA and around the world in the coming years.

[b]About Drugssquare[/b]

Over the years since its beginning, Drugssquare has grown organically with a strong foundation and fundamental values of service, quality and integrity. With continued strong demand for their products worldwide and an aggressive research program that evaluates exciting new ideas each year to deliver a steady stream of product innovations, They look forward to the opportunities and solutions of the future. Drugssquare.com is run by an enthusiastic and experienced team of professionals who encourage each other in experience and skills. Together we bring in extensive expertise and experience in Healthcare, Technology, Operations and Customer happiness.

[b]Contact Details:[/b]
Email: [email protected]
Web: http://www.drugssquare.com

[b]Source:[/b] https://www.prlog.org/12653669-drugssquare-declares-inclusion-of-hertraz-trastuzumb-injection-in-their-product-inventory.html